CN114146051B - 生肌愈疡中药凝胶剂及其制备方法 - Google Patents
生肌愈疡中药凝胶剂及其制备方法 Download PDFInfo
- Publication number
- CN114146051B CN114146051B CN202111363894.7A CN202111363894A CN114146051B CN 114146051 B CN114146051 B CN 114146051B CN 202111363894 A CN202111363894 A CN 202111363894A CN 114146051 B CN114146051 B CN 114146051B
- Authority
- CN
- China
- Prior art keywords
- parts
- gel
- traditional chinese
- chinese medicine
- tissue regeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 46
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 46
- 230000001737 promoting effect Effects 0.000 title claims abstract description 35
- 230000017423 tissue regeneration Effects 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title abstract description 21
- 239000011159 matrix material Substances 0.000 claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 19
- 241001071917 Lithospermum Species 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 10
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940116229 borneol Drugs 0.000 claims abstract description 9
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 9
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 244000173853 Sanguisorba officinalis Species 0.000 claims abstract description 8
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract description 8
- 240000004824 Trimezia steyermarkii Species 0.000 claims abstract description 8
- 239000009136 dragon's blood Substances 0.000 claims abstract description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 6
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 22
- 229920002125 Sokalan® Polymers 0.000 claims description 22
- 229960001631 carbomer Drugs 0.000 claims description 22
- 239000008213 purified water Substances 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 14
- 230000008961 swelling Effects 0.000 claims description 14
- 238000000227 grinding Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 239000009286 sanguis draxonis Substances 0.000 claims description 9
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 238000002386 leaching Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 3
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000035876 healing Effects 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 241000382455 Angelica sinensis Species 0.000 abstract description 5
- 238000005469 granulation Methods 0.000 abstract description 4
- 230000003179 granulation Effects 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000001338 necrotic effect Effects 0.000 abstract description 3
- 241000972672 Phellodendron Species 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 238000012795 verification Methods 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 239000013641 positive control Substances 0.000 description 9
- 206010040943 Skin Ulcer Diseases 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 208000000114 Pain Threshold Diseases 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003906 humectant Substances 0.000 description 5
- 239000003961 penetration enhancing agent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010002180 Anal ulcer Diseases 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000125175 Angelica Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000034493 Mucous membrane disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003167 anti-vitamin Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000009442 healing mechanism Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明提供了一种生肌愈疡中药凝胶剂及其制备方法,该生肌愈疡中药凝胶剂包括100~400重量份数的活性成分和200~400重量份数的凝胶基质,所述活性成分由以下重量份数的原料制成:紫草10~50份、白芷10~50份、当归30~100份、甘草30~100份、血竭10~40份、地榆10~50份、冰片10~20份、黄柏1~10份。本发明的中药制剂采用紫草、白芷、当归、甘草、血竭、地榆、冰片、黄柏配伍,行解毒敛疮、养血活血、祛腐生肌的功效,本发明的凝胶基质流动性适宜、易于涂展、与皮肤亲和力好,与中药复方提取液相容性好,能缓慢平稳释放药物,有利于提高药物的生物利用度。经临床验证,本发明生肌愈疡中药凝胶剂具有解毒敛疮、养血活血、祛腐生肌的功效。
Description
技术领域
本发明涉及医药技术领域,特别是涉及一种生肌愈疡中药凝胶剂及其制备方法。
背景技术
随着我国人口老龄化速度的加快,皮肤溃疡患者逐级递增。除了烧伤烫伤、机械创伤直接引起的皮肤溃疡以外,常以糖尿病、动脉硬化、心脑血管疾病等疾病并发症的形式出现。由于其发病率较高,难以在较短时间内痊愈的特点,使得患者在疾病治疗的过程更为棘手。慢性皮肤溃疡(chronic skin ulcer,CSU)又称难治性溃疡,是外科临床常见病、多发病,具有病因复杂、迁延难愈、愈后极易复发等特点。它包括血管性溃疡、压迫性溃疡、放射性溃疡及感染性溃疡等。近年来的研究表明,这类创面尽管不能迅速致人死亡,但是由于它发生在体表,在肉体和精神上给患者带来极大的痛苦,严重影响了患者的正常生活。慢性皮肤溃疡的愈合机制尚未完全了解,目前无特效药物及疗法。西医治疗常用的清创术、皮肤移植、抗感染或给予维生素类和锌治疗等方面基本停留在等待伤口自愈阶段,这些方法对病程短的早期溃疡效果较好,但对年龄大、病程久的慢性溃疡疗效则较差。因此,对慢性皮肤溃疡的处理,到目前为止仍然缺乏规范的治疗方法。
传统中药以生肌理论指导临床治疗,形成了独特的风格和体系。正如清·徐灵胎《医学源流论》中所说:“外科之法,最重外治。”本病的中医治疗,应以“外治为主,内治为辅。”中医药外治疗法可以明显促进与加速创面愈合,减少瘢痕形成,提高愈合质量,尤其对创口晦暗、肉芽组织不鲜者,疗效更佳。目前治疗慢性皮肤溃疡的外用药内容丰富,常用外用药的剂型有凝胶剂、乳膏剂、溶液剂、油膏剂、酊剂。
随着现代医药科技的发展,中医药也有了很大的进步,中药凝胶剂就是在传统中药制剂的基础上结合现代医药技术研制出来的凝胶类药物。中药凝胶剂是一种新型的中药外用制剂,它具有涂展性好、无油腻感、易于清洗、透皮吸收好等特点。凝胶剂是指药材提取物与适宜基质制成的、具有凝胶特性的半固体或稠厚液体制剂。中药凝胶剂常用于皮肤或黏膜疾病的治疗,其在对患者进行治疗的过程中,具有药力发挥的时间长及药物的起效快等优势。但具有生肌愈疡效果的中药凝胶剂尚未见报道。
发明内容
本发明的目的在于克服现有技术的不足,提供一种生肌愈疡中药凝胶剂及其制备方法。
本发明的技术方案为:
一种生肌愈疡中药凝胶剂,包括100~400重量份数的活性成分和200~400重量份数的凝胶基质,所述活性成分由以下重量份数的原料制成:紫草10~50份、白芷10~50份、当归30~100份、甘草30~100份、血竭10~40份、地榆10~50份、冰片10~20份、黄柏1~10份。
其中,所述凝胶基质由以下重量份数的组份制成:凝胶骨架材料1~30份、保湿剂100~500份、促渗剂10~20份、50~95v/v%的乙醇1000~4000份和纯化水600~800份。
优选的,所述凝胶骨架材料为卡波姆。
优选的,所述凝胶骨架材料为1~30份的卡波姆。
优选的,所述卡波姆为卡波姆980NF。
优选的,所述保湿剂为甘油、丙二醇、山梨醇中的至少一种,所述促渗剂为氮酮、薄荷醇、冰片中的至少一种。
优选的,所述活性成分由以下重量份数的原料制成:紫草30份、白芷30份、当归60份、甘草60份、血竭10份、地榆30份、冰片10份、黄柏10份。
一种生肌愈疡中药凝胶剂的制备方法,包括以下步骤:
1、将白芷、当归、甘草、地榆、黄柏混合加入适量乙醇中,采用水煎煮法进行提取,浓缩干燥成干浸膏;
2、将紫草加入适量乙醇中,40℃水浴浸提,合并提取液,减压浓缩成浸膏;
3、将干浸膏、紫草浸膏溶解于纯化水中,备用;
4、将血竭、甘油、冰片研磨均匀,再加入丙二醇研磨均匀,备用;
5、将卡波姆加入纯化水中,充分搅拌溶胀,再加三乙醇胺调pH;
6、依次加入步骤3、4中的备用物料于凝胶基质中,搅拌均匀,得到生肌愈疡凝胶剂;
其中,生肌愈疡凝胶剂的各成份的重量份数如上所述。
优选的,步骤3中,先取纯化水倒入容器中,缓慢均匀加入卡波姆,充分溶胀,再加三乙醇胺调pH至7~8。
本发明的中药制剂采用紫草、白芷、当归、甘草、血竭、地榆、冰片、黄柏配伍,行解毒敛疮、养血活血、祛腐生肌的功效。经临床验证,本发明提供的生肌愈疡中药凝胶剂具有解毒敛疮、养血活血、祛腐生肌的功效。
本发明的凝胶基质流动性适宜、易于涂展、与皮肤亲和力好,与中药复方提取液相容性好,能缓慢平稳释放药物,有利于提高药物的生物利用度。本发明提供的生肌愈疡中药凝胶剂具有涂展性好、无油腻感、易于清洗、透皮吸收好等特点。
本发明的生肌愈疡凝胶制剂由中药成分和无毒原料制成,涂抹于皮肤上,不仅生肌愈疡效果显著,而且对人体副作用小,不会刺激皮肤,可批量生产。
具体实施方式
为了便于理解本发明,下面将参照各实施例对本发明进行更全面的描述,但是,本发明可以以许多不同的形式来实现,并不限于本文所描述的实施例。相反地,提供这些实施例的目的是使对本发明的公开内容更加透彻全面。
除非另有定义,本文所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本文中在本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不是旨在于限制本发明。本文所使用的术语“及/或”包括一个或多个相关的所列项目的任意的和所有的组合。
本发明提供一种生肌愈疡中药凝胶剂,包括100~400重量份数的活性成分和200~400重量份数的凝胶基质,所述活性成分由以下重量份数的原料制成:紫草10~50份、白芷10~50份、当归30~100份、甘草30~100份、血竭10~40份、地榆10~50份、冰片10~20份、黄柏1~10份。
凝胶基质由以下重量份数的组份制成:凝胶骨架材料1~30份、保湿剂100~500份、促渗剂10~20份、50~95v/v%的乙醇1000~4000份和纯化水600~800份。
更优选的,该中药凝胶剂包括235重量份数的活性成分和2460重量份数的凝胶基质,所述活性成分由以下重量份数的原料制成:紫草30份、白芷30份、当归60份、甘草60份、血竭10份、地榆30份、冰片10份、黄柏10份;凝胶基质由以下重量份数的组份制成:凝胶骨架材料10份、保湿剂240份、促渗剂10份、95v/v%的乙醇1200份和纯化水1000份。
优选的,凝胶骨架材料为卡波姆。
优选的,凝胶骨架材料为1~30重量份的卡波姆。
优选的,卡波姆为卡波姆980NF。
优选的,保湿剂为甘油、丙二醇、山梨醇中的至少一种,促渗剂为氮酮、薄荷醇、冰片中的至少一种。
一种生肌愈疡中药凝胶剂的制备方法,包括以下步骤:
1、将白芷、当归、甘草、地榆、黄柏混合加入适量乙醇中,采用水煎煮法进行提取,浓缩干燥成干浸膏;
2、将紫草加入适量乙醇中,40℃水浴浸提,合并提取液,减压浓缩成浸膏;
3、将干浸膏、紫草浸膏溶解于纯化水中,备用;
4、将血竭、甘油、冰片研磨均匀,再加入丙二醇研磨均匀,备用;
5、将卡波姆加入纯化水中,充分搅拌溶胀,再加三乙醇胺调pH;
6、依次加入步骤3、4中的备用物料于凝胶基质中,搅拌均匀,得到生肌愈疡凝胶剂;
其中,生肌愈疡凝胶剂的各成份的重量份数如上所述。
优选的,步骤3中,先取纯化水倒入容器中,缓慢均匀加入卡波姆,充分溶胀,再加三乙醇胺调pH至7~8。
下面结合实施例,进一步阐述本发明内容。
以下实施例中所用辅料购买于西陇化工股份有限公司,若无特别说明,实施例中所述份数均为重量份。
实施例1
凝胶骨架材料的选择:
(1)凝胶剂配方:
其中,凝胶基质分别选用基质卡波姆980NF、卡波姆940NF、羧甲基纤维素钠、羟丙甲基纤维素、壳聚糖、泊洛沙姆进行筛选,按照配方量制成凝胶基质,对基质的成型性、细腻性2个指标进行考察,从而优选出能在短时间内制成涂展性、亲水性较好的基质。结果见表1。
表1不同基质制成凝胶基质的性能对比
可见,卡波姆980NF制备的凝胶均匀、细腻、光泽感好、粘稠适中,可均匀涂布。
实施例2
生肌愈疡中药凝胶剂的制备。本实施例所用中药饮片:紫草、白芷、当归、甘草、血竭、地榆、冰片、黄柏,上述九味中药饮片均购买于江西江中饮片有限公司。该中药凝胶剂包括120重量份数的活性成分和1250重量份数的凝胶基质,所述活性成分由以下重量份数的原料制成:
其中,药物活性成分配下:
凝胶剂配方:
制备方法:
1、按配方量将白芷、当归、甘草、地榆、黄柏五味中药饮片加8倍量75%乙醇煎煮两次,煎煮1小时,合并煎煮液,过滤,浓缩干燥成干浸膏;
2、按配方量将紫草加入8倍量95%乙醇中,40℃水浴浸提,提取3次,每次2小时,减压浓缩成浸膏;
3、将干浸膏、紫草浸膏溶解于200g纯化水中,备用;
4、按配方量将血竭、甘油、冰片研磨均匀,再加入丙二醇研磨均匀,备用;
5、将卡波姆加入1000g纯化水中,充分搅拌溶胀,再加三乙醇胺调pH;
6、依次加入步骤3、4中的备用物料于凝胶基质中,搅拌均匀,得到生肌愈疡凝胶剂。
实施例3
生肌愈疡中药凝胶剂的制备。本实施例所用中药饮片:紫草、白芷、当归、甘草、血竭、地榆、冰片、黄柏,上述九味中药饮片均购买于江西江中饮片有限公司。该中药凝胶剂包括260重量份数的活性成分和1250重量份数的凝胶基质,所述活性成分由以下重量份数的原料制成:
其中,药物活性成分配下:
凝胶剂配方:
制备方法:
1、按配方量将白芷、当归、甘草、地榆、黄柏五味中药饮片加8倍量75%乙醇煎煮两次,煎煮1小时,合并煎煮液,过滤,浓缩干燥成干浸膏;
2、按配方量将紫草加入8倍量95%乙醇中,40℃水浴浸提,提取3次,每次2小时,减压浓缩成浸膏;
3、将干浸膏、紫草浸膏溶解于200g纯化水中,备用;
4、按配方量将血竭、甘油、冰片研磨均匀,再加入丙二醇研磨均匀,备用;
5、将卡波姆加入1000g纯化水中,充分搅拌溶胀,再加三乙醇胺调pH;
6、依次加入步骤3、4中的备用物料于凝胶基质中,搅拌均匀,得到生肌愈疡凝胶剂。
实施例4
生肌愈疡中药凝胶剂的制备。本实施例所用中药饮片:紫草、白芷、当归、甘草、血竭、地榆、冰片、黄柏,上述九味中药饮片均购买于江西江中饮片有限公司。该中药凝胶剂包括430重量份数的活性成分和1250重量份数的凝胶基质,所述活性成分由以下重量份数的原料制成:
其中,药物活性成分配下:
凝胶剂配方:
制备方法:
1、按配方量将白芷、当归、甘草、地榆、黄柏五味中药饮片加8倍量75%乙醇煎煮两次,煎煮1小时,合并煎煮液,过滤,浓缩干燥成干浸膏;
2、按配方量将紫草加入8倍量95%乙醇中,40℃水浴浸提,提取3次,每次2小时,减压浓缩成浸膏;
3、将干浸膏、紫草浸膏溶解于200g纯化水中,备用;
4、按配方量将血竭、甘油、冰片研磨均匀,再加入丙二醇研磨均匀,备用;
5、将卡波姆加入1000g纯化水中,充分搅拌溶胀,再加三乙醇胺调pH;
6、依次加入步骤3、4中的备用物料于凝胶基质中,搅拌均匀,得到生肌愈疡凝胶剂。
试验例1
动物试验:
止痛实验
取健康小鼠(25±2g),适应性喂养3天后,用ZH-YLS智能热板仪于55±0.5℃测定各组小鼠的痛阈值。实验前选取痛阈值在10~30s内的小鼠,按照体质量水平随机分为5组,即模型组(生理盐水)、阳性对照组(烧伤止痛药膏)、凝胶剂1#组(所用凝胶剂来自实施例2),凝胶剂2#组(所用凝胶剂来自实施例3),凝胶剂3#组(所用凝胶剂来自实施例4)。各组小鼠2只后足涂抹相应的受试药物,分别记录给药30和90min后小鼠的痛阈值。结果见表2。
表2不同用药组对小鼠痛阈值的影响(±s,n=10)
由表2可见,生肌愈疡凝胶制剂在给药30min后能显著提高小鼠的痛阈值,而在给药90min后未能改变痛阈值,镇痛作用与烧伤止痛药膏相似。
对甲醛诱发的小鼠疼痛模型的影响
取健康小鼠(25±2g),对小鼠脱毛,按照体质量水平随机分为5组,即模型组(生理盐水)、阳性对照组(烧伤止痛药膏)、凝胶剂1#组(所用凝胶剂来自实施例2),凝胶剂2#组(所用凝胶剂来自实施例3),凝胶剂3#组(所用凝胶剂来自实施例4)。在实验前,小鼠禁食不禁水12h,末次给药2小时后,各组小鼠均以2.5%甲醛溶液于右后爪足跖底部皮下注射致痛,用量为0.03mL,注射完毕后立即用秒表计时,观察0-10分钟及10-30分钟之内,小鼠在这两个时间阶段内舔(抓、咬)右后足的累计时间。结果见表3。
表3不同用药组对甲醛诱发的小鼠疼痛模型的结果(±s,n=10)
*P<0.05(*表示与模型组比较)
结果表明,对甲醛诱发的小鼠疼痛模型的结果中发现,模型组的Ⅰ相神经疼痛期较凝胶剂2#组、3#组长,具有差异,但与阳性对照组比较,没有差异,但疼痛时间有下降趋势,说明凝胶剂2#组、3#组缩短了Ⅰ相神经疼痛期,对神经疼痛具有一定的疗效;Ⅱ相炎性疼痛期结果显示液、凝胶制剂组与模型组比较,缩短了炎性疼痛期,较阳性对照组比较,其疼痛期缩短更为明显,说明该凝胶制剂与阳性对对照组对炎性疼痛均有疗效。
对二甲苯致小鼠耳廓肿胀度的影响
取健康小鼠(25±2g),对小鼠脱毛,按照体质量水平随机分为5组,即模型组(生理盐水)、阳性对照组(烧伤止痛药膏)、凝胶剂1#组(所用凝胶剂来自实施例2),凝胶剂2#组(所用凝胶剂来自实施例3),凝胶剂3#组(所用凝胶剂来自实施例4)。在实验前,小鼠禁食不禁水12h,右耳涂二甲苯0.03mL,左耳不涂药,作为自身对照。造模15分钟后,除模型组外,各组分别涂相应的药物。0.5h后处死小鼠,用手术剪剪取左右耳,用打孔器在两耳相对称位置进行打孔,称量,计算其肿胀度(左右耳重量之差)及肿胀抑制率=(模型组平均肿胀度-给药组平均肿胀度)/模型组平均肿胀度×100%。结果见表4。
表4对二甲苯致小鼠耳廓肿胀度的结果(±s,n=10)
结果显示,模型组与阳性对照组、凝胶剂组比较,耳廓肿胀度差异显著,说明该方法造模成功,但阳性对照组与凝胶剂组比较,并没有差异。
大鼠肛周溃疡面愈合实验
取SD大鼠,在其肛门外周注射冰醋酸0.05/只,致溃疡,随机分为模型组(凡士林基质)、阳性对照组(马应龙麝香痔疮膏)、凝胶剂1#组(所用凝胶剂来自实施例2),凝胶剂2#组(所用凝胶剂来自实施例3),凝胶剂3#组(所用凝胶剂来自实施例4),每组12只。每组均匀涂试药1.0g次,3次/d,观察溃疡面红肿、组织炎性渗出及溃疡面的愈合时间(以伤口结痴脱落为痊愈)。溃疡程度评定标准:有溃疡渗出液1分,有少量溃疡渗出液2分,有结痂、基本愈合3分,完全愈合4分。结果见表5。
表5对大鼠肛周溃疡面愈合度的结果(±s,n=12)
大鼠肛周溃疡面愈合实验结果致溃疡后第6、8、10天,凝胶制剂组溃疡程度评分均大于模型组,差异均有统计学意义(P<0.05)。致溃疡后第8、10天,马应龙麝香痔疮膏组溃疡程度评分均大于模型组,差异有统计学意义(P<0.05)
综上,本发明中药制剂需要较大的载药量才能更好的发挥疗效,本发明凝胶基质能吸收大量中药提取液,形成稳定的凝胶体,大大提高了凝胶剂的载药量,从而提高了生肌愈疡的功效。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (2)
1.一种生肌愈疡中药凝胶剂,其特征在于,包括430重量份数的活性成分和1250重量份数的凝胶基质,所述活性成分由以下重量份数的原料制成:紫草50份、白芷50份、当归100份、甘草100份、血竭30份、地榆60份、冰片20份、黄柏20份;
所述凝胶基质由以下重量份数的组份制成:凝胶骨架材料10份、甘油40份、丙二醇200份、水1000份;
所述凝胶骨架材料为卡波姆980NF。
2.权利要求1所述的生肌愈疡中药凝胶剂的制备方法,其特征在于,包括以下步骤:
1、按配方量将白芷、当归、甘草、地榆、黄柏五味中药饮片加8倍量75%乙醇煎煮两次,煎煮1小时,合并煎煮液,过滤,浓缩干燥成干浸膏;
2、按配方量将紫草加入8倍量95%乙醇中,40℃水浴浸提,提取3次,每次2小时,减压浓缩成浸膏;
3、将干浸膏、紫草浸膏溶解于200g纯化水中,备用;
4、按配方量将血竭、甘油、冰片研磨均匀,再加入丙二醇研磨均匀,备用;
5、将卡波姆980NF加入1000g纯化水中,充分搅拌溶胀,再加三乙醇胺调pH至7~8;
6、依次加入步骤3、4中的备用物料于凝胶基质中,搅拌均匀,得到生肌愈疡凝胶剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111363894.7A CN114146051B (zh) | 2021-11-17 | 2021-11-17 | 生肌愈疡中药凝胶剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111363894.7A CN114146051B (zh) | 2021-11-17 | 2021-11-17 | 生肌愈疡中药凝胶剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114146051A CN114146051A (zh) | 2022-03-08 |
CN114146051B true CN114146051B (zh) | 2024-02-20 |
Family
ID=80456500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111363894.7A Active CN114146051B (zh) | 2021-11-17 | 2021-11-17 | 生肌愈疡中药凝胶剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114146051B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116370565A (zh) * | 2023-04-21 | 2023-07-04 | 弘禾(海南)医疗科技有限公司 | 一种治疗痔疮的医用生物凝胶及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101648007A (zh) * | 2008-08-13 | 2010-02-17 | 代龙 | 一种用于治疗下肢溃疡的药物组合物及其制备方法 |
CN203342089U (zh) * | 2013-07-01 | 2013-12-18 | 崔证军 | 紫草油浸水刺无纺布外用贴 |
CN112426455A (zh) * | 2020-12-07 | 2021-03-02 | 宁夏医科大学总医院 | 一种紫草油组方及其制备方法与应用 |
-
2021
- 2021-11-17 CN CN202111363894.7A patent/CN114146051B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101648007A (zh) * | 2008-08-13 | 2010-02-17 | 代龙 | 一种用于治疗下肢溃疡的药物组合物及其制备方法 |
CN203342089U (zh) * | 2013-07-01 | 2013-12-18 | 崔证军 | 紫草油浸水刺无纺布外用贴 |
CN112426455A (zh) * | 2020-12-07 | 2021-03-02 | 宁夏医科大学总医院 | 一种紫草油组方及其制备方法与应用 |
Non-Patent Citations (4)
Title |
---|
复方紫草油的制备及临床应用;巩建国, 巩大庆;中国民间疗法;-;第-卷(第02期);27 * |
复方黄柏紫草地榆霜的制备及临床疗效观察;晁青;;菏泽医学专科学校学报;-;第-卷(第03期);19-20, 40 * |
烫疮油用于卧床老年病人摩擦红斑的护理研究;陈鸣明;杨东平;孟健;;护理研究;-;第-卷(第30期);2754-2755 * |
紫草素的提取工艺及制剂研究概况;王爱萍;郑茂东;李祯;;中国医药指南(第04期);90-93 * |
Also Published As
Publication number | Publication date |
---|---|
CN114146051A (zh) | 2022-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114146051B (zh) | 生肌愈疡中药凝胶剂及其制备方法 | |
CN113768975A (zh) | 一种治疗关节疼痛的中药组合物、中药贴剂及其制备方法与使用方法 | |
CN105287837A (zh) | 一种用于治疗痔疮的中药复方制剂及其制备方法 | |
CN110680879A (zh) | 一种活血止血祛腐生肌的中药喷膜剂及其制备方法 | |
CN101564487A (zh) | 一种竭红跌打药剂及其制备方法 | |
CN108434227A (zh) | 一种治疗脚气的药物 | |
CN108721442B (zh) | 治疗烧烫伤及尿布皮炎的中药组合物、制剂及其制备方法 | |
WO2001064229A1 (fr) | Medicament de traitement de l'obesite, sa preparation et son utilisation | |
CN108159360B (zh) | 一种牛蹄部损伤中药护蹄膏及其制备方法 | |
CN102836306B (zh) | 一种治疗马跌打损伤的中药组合物及其制备方法 | |
CN112773833A (zh) | 一种治疗复发性口疮的中药方剂及其制备方法 | |
CN106880654B (zh) | 竹节参提取物在制备治疗鼻炎药物中的应用及组合物 | |
CN116327828B (zh) | 一种用于轻中度烧烫伤的紫草牡丹籽油喷膜及其制备方法 | |
CN104721384A (zh) | 一种收敛药膏 | |
CN115414368B (zh) | 一种治疗跌打损伤的药物组合物及其应用 | |
CN111419952B (zh) | 一种具有止血止痛作用的中药组合物及其制备方法和应用 | |
CN109806321B (zh) | 一种中药组合物及其制法和在制备治疗外伤药物中的应用 | |
CN114886981B (zh) | 中药组合物及其在制备颈肩腰腿痛药中的应用 | |
CN114533859B (zh) | 一种治疗痔疮的中药药膏及其制备方法 | |
CN113230332B (zh) | 一种治疗糖尿病患者伤口溃烂不能愈合的药物、其制剂及制法 | |
CN112656896B (zh) | 一种治疗痔疮的外用中药组合物及其制备方法与应用 | |
CN102526387A (zh) | 一种治疗早期糖尿病足的药物组合物及制备方法 | |
CN108434299B (zh) | 用于治疗肩周炎的药物组合物及其制备方法与喷雾剂 | |
CN114377054B (zh) | 青钱柳叶或其提取物在制备预防和/或治疗痤疮的药物或化妆品中的用途 | |
CN117085059A (zh) | 一种治疗银屑病的外用蒙药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |